Operator
Good morning, everyone, and welcome to Compugen’s COM701 in Ovarian Cancer and Unigen Platform Update Event. [Operator Instructions] Before handing the call over to the company, please review the forward-looking statements on this slide.
I’d now like to introduce Dr. Eran Ophir, President and Chief Executive Officer of Compugen. Eran, please go ahead.
Eran Ophir
CEO, President & Director
Good morning, everyone, and thank you for joining us. I’m Eran Ophir, President and CEO of Compugen. Today, we’ll provide a brief overview of Compugen’s key value drivers, discuss the clinical opportunity for COM701, our first-in-class anti-PVRIG antibody being studied as maintenance therapy in second- and third-line platinum-sensitive ovarian cancer, and share an update on the continued evolution of Unigen, our AI-powered discovery platform.
Dr. Oladapo Yeku, the lead investigator on our MAIA-ovarian adaptive platform trial from Harvard and Mass General Hospital will share his perspective on the evolving treatment landscape in ovarian cancer, setting the stage for the interim analysis of the MAIA study with PFS readout that is expected to be reported by Q1 2027.
Later on, Dr. Sharon Kredo-Russo, our Senior Vice President of Research and Discovery, will discuss how we are expanding Unigen’s capabilities to support Compugen’s next generation of immune oncology discovery. While we will not be disclosing any new targets today, we believe it is
